These include Bempegaldesleukin (BEMPEG/NKTR-214), a CD122-preferential IL-2 pathway agonist demonstrating promising anti-tumour efficacy in pre-clinical studies of advanced cancer in combination with ICB and local radiation therapy [82]. The gene discussed is IL2; the disease is neoplasm.